Prevalence of diabetes complications in first line therapy of type 2 diabetes mellitus in a middle size town of Romania

2010 ◽  
Vol 6 (3) ◽  
pp. 327-334
Author(s):  
Sorin Ioacara
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetes Complications ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

An Evaluation for Diabetic patient by measuring FDCs

2020 ◽  
Vol 5 (2) ◽  
pp. 22-25
Author(s):  
Vurimi Chaitanya Sai Manikanta
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Single Dose ◽  
Fixed Dose ◽  
Indian Market ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Type 2 diabetes mellitus (T2DM) is an enlightened diseases with multifactorial etiology. The first-line therapy includes monotherapy, which often fails to achieve effective glycemic control, necessitating the addition of add-on therapy. In this regard, multiple single-dose combinations called fixed-dose combinations (FDCs) have been evaluated for their safety, efficacy, and tolerability. To analyze the rationality of diverse FDCs used in the remedy Diabetes Mellitus and to find out the irrational FDCs existing in Indian market. A overall of 18 mixtures had been analyzed, amongst the ones 11 combinations had been irrational. Predominantly irrational FDCs are being circulated within the Indian market as a result thru analyses by way of prescribers is wanted earlier than prescribing to patients a good way to keep away from ADR. This requires a near scrutiny of advertised FDCs and educating prescribers to apply them with first rate care and caution also suggests an extreme evaluation of regulatory framework for drug production and marketing. An assessment of the pharmacology and scientific consequences from current hearings of the metformin-sitagliptin mixture and the way the mixture could in shape into the sort 2 diabetes remedy algorithms is obtainable on the evaluation.

Bismuth-Based First-Line Therapy for Helicobacter pylori Eradication in Type 2 Diabetes Mellitus Patients

Digestion ◽  
2010 ◽  
Vol 82 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Mehmet Demir ◽  
Savaş Göktürk ◽  
Nevin Akçaer Öztürk ◽  
Ender Serin ◽  
Uğur Yilmaz
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Helicobacter Pylori ◽  
Type 2 Diabetes Mellitus ◽  
First Line ◽  
Helicobacter Pylori Eradication ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia

2021 ◽  
Vol 6 (1) ◽  
pp. 238146832110057
Author(s):  
Mengistu Bekele ◽  
Ole Frithjof Norheim ◽  
Alemayehu Hailu
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
Line Therapy

Background. Metformin is a widely accepted first-line pharmacotherapy for patients with type 2 diabetes mellitus (T2DM). Treatment of T2DM with glibenclamide, saxagliptin, or one of the other second-line treatment agents is recommended when the first-line treatment (metformin) cannot control the disease. However, there is little evidence on the additional cost and cost-effectiveness of adding second-line drugs. Therefore, this study aimed to estimate the cost-effectiveness of saxagliptin and glibenclamide as second-line therapies added to metformin compared with metformin only in T2DM in Ethiopia. Methods. This cost-effectiveness study was conducted in Ethiopia using a mix of primary data on cost and best available data from the literature on the effectiveness. We measured the interventions’ cost from the providers’ perspective in 2019 US dollars. We developed a Markov model for T2DM disease progression with five health states using TreeAge Pro 2020 software. Disability-adjusted life year (DALY) was the health outcome used in this study, and we calculated the incremental cost-effectiveness ratio (ICER) per DALY averted. Furthermore, one-way and probabilistic sensitivity analysis were performed. Results. The annual unit cost per patient was US$70 for metformin, US$75 for metformin + glibenclamide, and US$309 for metformin + saxagliptin. The ICER for saxagliptin + metformin was US$2259 per DALY averted. The ICER results were sensitive to various changes in cost, effectiveness, and transition probabilities. The ICER was driven primarily by the higher cost of saxagliptin relative to glibenclamide. Conclusion. Our study revealed that saxagliptin is not a cost-effective second-line therapy in patients with T2DM inadequately controlled by metformin monotherapy based on a gross domestic product per capita per DALY averted willingness-to-pay threshold in Ethiopia (US$953).

Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted?

Diabetes Care ◽  
2008 ◽  
Vol 31 (Supplement 2) ◽  
pp. S136-S139 ◽  
Author(s):  
E. Standl ◽  
O. Schnell
Keyword(s):  
Type 2 Diabetes ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes

2009 ◽  
Vol 25 (9) ◽  
pp. 2239-2249 ◽  
Author(s):  
Michael R. Jones ◽  
Sunder Mudaliar ◽  
Eric Hernandez-Triana ◽  
Ambika G. Unnikrishnan ◽  
Yu-Ling Lai ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document